News | Peripheral Artery Disease (PAD)

November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded trial ...

Home November 14, 2019
Home
News | AHA

November 14, 2019 — More than a million Americans face a doubling in their risk of death during or while recovering from ...

Home November 14, 2019
Home
News | AHA

November 14, 2019 — A new study from researchers at the Smidt Heart Institute at Cedars-Sinai shows that electronic ...

Home November 14, 2019
Home
News | Peripheral Artery Disease (PAD)

November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the ...

Home November 14, 2019
Home
News | AHA

November 14, 2019 — A large majority of patients with atherosclerotic cardiovascular disease (ASCVD) in the NCDR ...

Home November 14, 2019
Home
News | Drug-Eluting Balloons

November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the ...

Home November 14, 2019
Home
Viva conference late breaking clinical trials, #VIVA19 #VIVA #VIVA2019
Feature | VIVA

November 14, 2019 — The results of the 21 late-breaking clinical trials presented for the first time at Vascular ...

Home November 14, 2019
Home
News | Cardiovascular Ultrasound

November 14, 2019 — Ultromics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Home November 14, 2019
Home
News | Pacemakers

https://www.dicardiology.com/channel/pacemakersTexas Heart Institute (THI) was awarded a prestigious four-year, $2.39 million grant from the National Institutes of Health (NIH) to explore further the development of a novel pacemaker system that is both leadless and wirelessly powered.

Home November 13, 2019
Home
News | Atherectomy Devices

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

Home November 11, 2019
Home
News | Endovascular Aortic Repair

November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for ...

Home November 11, 2019
Home
News | Stents Carotid

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment ...

Home November 11, 2019
Home
Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.
Feature | EP Lab | Hrishikesh Kadam

Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing ...

Home November 11, 2019
Home
News | Cardiovascular Business

November 11, 2019 — ECG Management Consultants, a leading U.S. healthcare advisory firm, is now part of the global ...

Home November 11, 2019
Home
Subscribe Now